COMMITMENTS AND CONTINGENCIES (Details) - Licensing Agreements			1 Months Ended
	Dec. 10, 2015 USD ($)	Jun. 10, 2015 USD ($) product	Mar. 31, 2016 USD ($)
Baylor
Loss Contingencies [Line Items]
Nonrefundable license fee			$ 100,000
Agensys, Inc.
Loss Contingencies [Line Items]
Nonrefundable upfront fee	$ 3,000,000.0
Milestone payments upon first achievement of specified clinical milestones	5,000,000.0
Milestone payments upon achievement of specified clinical milestones for each licensed product	50,000,000.0
Milestone payments upon achievement of sales milestones	75,000,000.0
Option exercise fee	5,000,000.0
Milestone payments reduced upon exercise of option	$ 65,000,000.0
Termination period, number of years after first commercial sale of licensed product	10 years
Termination period, notice of failure on uncured items	60 days
Period of notice of failure on uncured items, if material breach is related to failure to make payments	30 days
BioVec Pharma Inc
Loss Contingencies [Line Items]
Nonrefundable upfront fee		$ 100,000
Milestone payments upon first achievement of specified clinical milestones		$ 250,000
Termination period, notice of failure on uncured items		60 days
Upfront fee payment period, number of days from effective date		10 days
License costs due upon first release of product		$ 300,000
License costs due upon first release of product, period of payment		10 days
License agreement, annual fee		$ 150,000
License agreement, annual fee period, from first IND filing		30 days
Milestone payments, number of initial products | product		3
License agreement, milestone payments upon receipt of FDA or EMA registration		$ 2,000,000.0
Termination notice period for any other breach		90 days
Termination period, after insolvency event		30 days